Oral contraceptives, hormone therapy and cardiovascular risk

References

• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia H J, Johnson K C, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–524
   PubMed Web of Science ®Google Scholar
• Prentice R L, Langer R D, Stefanick M L, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006; 163: 589–599
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Prentice R L, Manson J E, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–1477
   PubMed Web of Science ®Google Scholar
• Manson J E, Bassuk S S. Invited commentary: Hormone therapy and risk of coronary heart disease – why renew the focus on the early years of the menopause?. Am J Epidemiol 2007; 166: 511–517
   PubMed Web of Science ®Google Scholar
• Royal College of General Practitioners. Oral contraceptives, venous thromboembolism, and varicose veins. Royal College of General Practitioners Oral Contraception Study. J R Coll Gen Pract 1978; 28: 393–399
   PubMedGoogle Scholar
• Farmer R D, Lawrenson R A, Todd J, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000; 49: 580–590
   PubMed Web of Science ®Google Scholar
• Farley T M, Meirik O, Marmot M G, Chang C L, Poulter N R. Oral contraceptives and the risk of venous thromboembolism: impact of duration of use. Contraception 1998; 57: 61–65
   PubMed Web of Science ®Google Scholar
• Suissa S, Spitzer W O. Oral contraceptives and the risk of venous thromboembolism: impact of duration of use. Contraception 1998; 57: 64–65
   Web of Science ®Google Scholar
• Ridker P M, Mileticj J P, Stampfer M J, Goldhaber S Z, Lindpaintner K, Hennekens C H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800–2802
   PubMed Web of Science ®Google Scholar
• Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504–1508
   PubMed Web of Science ®Google Scholar
• Lewis M A, Heinemann L AJ, MacRae K D, Bruppacher R, Spitzer W O, Transnational Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5–13
   PubMed Web of Science ®Google Scholar
• Lewis M A, MacRae K D, Kuhl-Habichl D, Bruppacher R, Heinemann L A, Spitzer W O. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493–1499
   PubMed Web of Science ®Google Scholar
• Suissa S, Blais L, Spitzer W O, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–146
   PubMed Web of Science ®Google Scholar
• Heinemann L A, Assmann A, DoMinh T, Garbe E. Oral progestogen only contraceptives and cardiovascular risk: results of the Transnational Study on Oral Contraceptives and Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4: 67–73
   PubMedGoogle Scholar
• Bloemenkamp K W, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593–1596
   PubMed Web of Science ®Google Scholar
• Farley T MM, Meirik O, Chang C L, et al. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582–1588
   PubMed Web of Science ®Google Scholar
• Jick H, Jick S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progastagen components. Lancet 1995; 346: 1589–1593
   PubMed Web of Science ®Google Scholar
• Spitzer W O, Lewis M A, Heinemann L AJ, Thorogood M, MacRae K D, Transnational Research Group. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83–88
   PubMed Web of Science ®Google Scholar
• Kemmeren J M, Algra A, Grobbee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131–134
   PubMed Web of Science ®Google Scholar
• Lewis M A, Spitzer W O. Risk of oral contraceptives and recency of market introduction. Contraception 1997; 55: 192–194
   Web of Science ®Google Scholar
• Lewis M A, Spitzer W O, Heinemann L AJ, MacRae K D. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996; 312: 88–90
   PubMed Web of Science ®Google Scholar
• Suissa S, Spitzer W O, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15: 817–821
   PubMed Web of Science ®Google Scholar
• Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000; 151: 939–945
   PubMed Web of Science ®Google Scholar
• Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies?. J Clin Epidemiol 1997; 50: 223–229
   PubMed Web of Science ®Google Scholar
• Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003; 6: 302–310
   PubMed Web of Science ®Google Scholar
• Nelson H D, Humphrey L N, Nygren P, Allan J A. Postmenopausal hormone replacement therapy. Scientific review. JAMA 2002; 288: 872–882
   PubMed Web of Science ®Google Scholar